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Abstract— Although high-frequency ultrasound imaging is
gaining attention in various applications, hardly any ultrasound
contrast agents (UCAs) dedicated to such frequencies (>15 MHz)
are available for contrast-enhanced ultrasound (CEUS) imaging.
Moreover, the composition of the limited commercially available
UCAs for high-frequency CEUS (hfCEUS) is largely unknown,
while shell properties have been shown to be an important factor
for their performance. The aim of our study was to produce
UCAs in-house for hfCEUS. Twelve different UCA formulations
A-L were made by either sonication or mechanical agitation. The
gas core consisted of C4F10 and the main coating lipid was either
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC; A-F formu-
lation) or 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC;
G-L formulation). Mechanical agitation resulted in UCAs with
smaller microbubbles (number weighted mean diameter ∼1 µm)
than sonication (number weighted mean diameter ∼2 µm). UCA
formulations with similar size distributions but different main
lipid components showed that the DPPC-based UCA formula-
tions had higher nonlinear responses at both the fundamental
and subharmonic frequencies in vitro for hfCEUS using the
Vevo2100 high-frequency preclinical scanner (FUJIFILM Visu-
alSonics, Inc.). In addition, UCA formulations F (DSPC-based)
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and L (DPPC-based) that were made by mechanical agitation
performed similar in vitro to the commercially available Target-
Ready MicroMarker (FUJIFILM VisualSonics, Inc.). UCA for-
mulation F also performed similar to Target-Ready MicroMarker
in vivo in pigs with similar mean contrast intensity within the
kidney (n = 7), but formulation L did not. This is likely due
to the lower stability of formulation L in vivo. Our study shows
that DSPC-based microbubbles produced by mechanical agitation
resulted in small microbubbles with high nonlinear responses
suitable for hfCEUS imaging.
Index Terms— Contrast agent, contrast-enhanced ultra-
sound (CEUS) imaging, high-frequency, in vitro, in vivo,
microbubble.
I. INTRODUCTION
ULTRASOUND imaging at high frequencies (≥15 MHz)enables high-resolution imaging at the price of lower
penetration depth, making this technique highly suitable for
imaging of small animals [1] and superficial organs in large
animals (e.g., skin [2]) and humans (e.g., eye [3] and skin
tumors [4]). Alternatively, an endoscopic (e.g., transrectal [5])
or intravascular probe [6] could be used if the organ of interest
lies deeper within the body.
Contrast-enhanced ultrasound (CEUS) imaging allows
assessment of blood flow to improve diagnosis and monitor
therapy. For CEUS, intravenously injected ultrasound con-
trast agents (UCAs) are needed that consist of gas-coated
microbubbles dispersed in saline [7]–[9]. Examples of pre-
clinical high-frequency CEUS (hfCEUS) are tumor angiogen-
esis imaging [10] and cerebral microvascular hemodynamics
assessment in rats [11]. Microbubbles are effective UCAs with
a strong resonance structure and inherently nonlinear behavior
in response to a time-varying pressure field [10], [11]. These
nonlinear oscillations can be present at the subharmonic (SH),
fundamental, ultraharmonic, and higher harmonic frequency.
The nonlinear signals generated by the microbubbles are
utilized in imaging techniques to separate the UCA signal from
that of the surrounding tissue [12].
Methods based on the detection of higher harmon-
ics are hindered by artifacts when the excitation fre-
quency is high (≥15 MHz), such as nonlinear propagation
artifacts [13], [14]. In addition to those artifacts, higher har-
monics undergo dramatic attenuation because of their high
frequencies, which limits the penetration depth. Nonlinear
fundamental contrast imaging is the most common approach
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TABLE I
PRODUCTION OF MICROBUBBLES: COMPOSITION OF MICROBUBBLE PHOSPHOLIPID COATING, OTHER COATING COMPONENTS,
ADDITIVES, AND METHOD OF PRODUCTION; MB = MICROBUBBLE
for nonlinear hfCEUS imaging [12]. The nonlinear funda-
mental component suffers less from attenuation, but nonlinear
propagation is still a drawback. SH imaging, on the other
hand, is free from such artifacts, is less attenuated, and
neither generated during propagation in tissue nor scattered
by tissue [15]. An SH signal can be achieved with minimum
amplitude excitation if the driving frequency is twice the res-
onance frequency of the microbubbles [16], [17]. To increase
the sensitivity of hfCEUS, both the imaging techniques and
the UCA design need to be optimized.
The performance of UCAs highly depends on the reso-
nance behavior of a microbubble, which is inversely related
to its diameter [17], [18]. Therefore, UCAs with smaller
microbubbles can improve the sensitivity of hfCEUS imaging.
Next to size, microbubble shell properties have been shown
to be an important factor for their performance, mainly in
the generation of SH [19], [20]. The lipid composition of
the microbubble shell in the commercially available UCAs
for hfCEUS is known only for Definity [21], but unknown
for MicroMarker [22] and Targestar P-HF [23]. For high-
frequency ultrasound molecular imaging, functionalizing the
microbubbles is required to target them to the biomarker of
interest [24]. Although Target-Ready MicroMarker provides
streptavidin linkage [25], no UCA is commercially available
to provide covalent coupling of the ligand to the microbubble
shell, limiting flexibility in choice of ligands. In-house pro-
duced UCAs could overcome these disadvantages.
Based on a preliminary experiment we conducted
before [26], the aim of our study was to produce lipid-coated
UCAs in-house with high nonlinear response for hfCEUS.
Based on microbubble size, a resonance frequency can be
predicted [18], but the actual response still depends on the
shell microstructure, as we previously showed for the main
lipids used in commercially available UCAs [20], [21], [27]:
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) or
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC). We
therefore studied 12 different UCA types with the aim to
produce microbubbles with a size similar to Definity [21] and
MicroMarker [22]. UCAs were either produced by sonication,
i.e., the most common UCA production method [28],
or mechanical agitation, i.e., the method by which Definity
is prepared [21]. In addition, we compared the UCA
compositions we [29] and others [30], [31] have used
throughout the years, and quantitatively evaluated the
performance of the in-house produced UCAs to Target-Ready
MicroMarker in vitro and in vivo with hfCEUS using the
most commonly used high-frequency ultrasound imaging plat-
form (Vevo2100, FUJIFILM VisualSonics, Inc., Toronto, ON,
Canada).
II. MATERIALS AND METHODS
A. Ultrasound Contrast Agent Preparation
All UCAs were produced in phosphate-buffered saline
(PBS; Invitrogen, Groningen, the Netherlands) as the aqueous
medium. UCAs were either produced by probe sonication
at 20 kHz with a Sonicator Ultrasonic Processor XL2020
at setting 10 (Heat Systems, Farmingdale, NY, USA) as
previously described [29], [32] for 60, 90, or 120 s or by
mechanical agitation for 45 s using a Vial Shaker (Bristol-
Myers Squibb Medical Imaging, Inc., North Billerica, MA,
USA). UCAs with a C4F10 (F2 Chemicals, Preston, U.K.)
gas core and different phospholipid coating formulations
(see Table I) were made. The main phospholipid compo-
nent for all UCA formulations was either DSPC (P6517),
purchased from Sigma-Aldrich, Zwijndrecht, the Netherlands
(formulations A-F) or DPPC (850355), purchased from Avanti
Polar Lipids, Alabaster, AL, USA (formulations G-L). The
other coating components were polyoxyethylene (40) stearate
(PEG-40 stearate; P3440; Sigma-Aldrich), 1,2-diste-aroyl-
sn-glycero-3-phosphoethanolamine-N-carboxy (poly-ethylene
glycol) (DSPE-PEG2000; 880125; Avanti Polar Lipids), and
1, 2-distearoyl-sn-glycero-3-phosphoethanolamine-N-biotinyl
(polyethylene glycol) (DSPE-PEG2000-biotin; 880129; Avanti
Polar Lipids).
Coating formulations A-D and G-J were identical to our
previously produced UCAs made by sonication for 10 s
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(number weighted mean ∼4 µm) [29]. The UCAs made by
vial shaking either contained no glycerol and no propylene
glycol (formulation D and J) as reported in [33] and [34]
or contained 5% v/v glycerol (818709, Merck Millipore,
Merck, Amsterdam, the Netherlands) and 5% v/v propylene
glycol (82280, Sigma-Aldrich) (formulation E and K) as
reported in [31], or 10% v/v glycerol and 20% v/v propylene
glycol (formulation F and L) as reported in [30]. Our UCA
formulations E, F, K, and L contained only two different
lipids, which is typical for in-house produced UCAs made
by vial shaking [30], [35]–[37]. We chose DSPE-PEG2000 in
addition to the main lipid DSPC or DPPC because this lipid
can be utilized for targeting, whereas the PEG40-stearate
cannot [24]. The molar ratio of DSPC or DPPC to (DSPE-
PEG2000 + DSPE-PEG2000-biotin) was kept identical to
UCA formulations A-D and G-J.
UCAs produced by sonication (formulations A-C and
G-I) were put in 5-mL glass serum bottles (223738; Wheaton,
Millville, NJ, USA), topped with C4F10 gas, and closed with
a rubber stopper (Z166065; Sigma-Aldrich) and aluminum
cap (224193-01; Wheaton). Before the experiments, UCAs
made by sonication were washed three times by centrifugation
at 400 g for 1 min (Heraeus Biofuge, Thermo Scientific, Etten-
Leur, the Netherlands) to remove the excess lipids. For the
vial shaking method, 1 mL of the solution (lipid concentration
0.4 mg/mL for formulations D-F and J-L) was pipetted in a
2-mL glass screw top vial (5182-0714; Agilent Technologies,
Santa Clara, CA, USA), topped with C4F10 gas, and closed
with a screw cap (5182-0717; Agilent Technologies).
Target-Ready MicroMarker UCA was prepared from the
ready kit (FUJIFILM VisualSonics, Inc.) according to the
manufacturer’s instructions: the lyophilisate cake was recon-
stituted with 1 mL of 0.9% sodium chloride solution. The
microbubbles in this UCA consist of a phospholipid shell
encapsulating a C4F10/N2 gas core [22]. All UCAs were
produced or reconstituted not more than a few hours before the
experiments. Size distributions of the UCAs were measured
using a Coulter Counter (Multisizer 3, Beckman Coulter,
Mijdrecht, the Netherlands). A 20-µm aperture tube was used,
allowing quantification of particle diameters between 0.4 and
12 µm using a linear spacing between the 256 channels.
Measurements were repeated three times for each UCA to
obtain the mean microbubble diameter, size distribution, and
concentration. Polydispersity of the UCAs was calculated
by assessing the SPAN, which illustrates the width of the
distribution, using (d90%–d10%)/d50% where d10, d50, and
d90 are the microbubble number weighted diameters below
which 10%, 50%, and 90% of the cumulative amount of
number weighted microbubbles is found. Data are presented
with standard deviations (SDs).
B. In Vitro hfCEUS Imaging and Quantification
A schematic of our experimental setup is depicted in Fig. 1.
The 10-mm diameter thin shell cylindrical tube, made of
polypropylene film backing and coated with a water-based
acrylic adhesive having a total thickness of 52 µm (Tesa
4024 PV 2), was mounted in a water tank with its center at
the focus (18 mm) of the imaging probe. The tube was filled
Fig. 1. Experimental setup for the in vitro characterization of the UCA.
with 15 mL air-saturated PBS. UCA dilutions were pipetted
in the tube and mixed gently using a magnetic stirrer in order
to have a homogeneous suspension. For the first B-mode scan,
the UCA concentration was 5 × 104 microbubbles/mL. Next,
the effect of the UCA concentration on SH imaging was tested
for selected UCAs using two concentrations: 8 × 106 and
4 × 105 microbubbles/mL, hereafter referred to as high and
low concentration, respectively. All measurements were con-
ducted within 10 min after pipetting the UCA suspensions into
the tube. For each new UCA or dilution, the tube was washed
with distilled air-saturated water, filled with air-saturated PBS,
and placed in the same location in the water tank.
We used a high-frequency preclinical ultrasound scanner
operated at 15 or 30 MHz, with two linear array transducers
[MS200 probe (15 MHz) and MS250 probe (30 MHz), FUJI-
FILM VisualSonics, Inc.]. The wide beamwidth setting was
chosen in order to have a low more uniform transmit pressure
over depth in the tube [12]. To study the scattering properties
of all 12 UCA formulations, the MS200 probe was used at
15-MHz transmit frequency at 1% transmit power and one
cycle pulse duration in B-mode. On the selected UCA formula-
tions (C, I, F, L, and Target-Ready MicroMarker), SH imaging
was performed with the MS250 probe. This probe has a center
frequency of 22.5 MHz and a −6-dB two-way bandwidth
of 70% (15–30 MHz) [12], therefore suitable for SH imaging
if transmitting at 30 MHz. The selection of the SH imaging
parameters such as transmit frequency (30 MHz), power (10%
corresponding to a peak-to-peak pressure of ∼200 kPa), pulse
sequence (pulse inversion [12]), and length (20 cycles for bet-
ter separation of the SH component in the frequency domain)
were based on a previous study in which these parameters were
optimized for SH imaging [15]. The focus of the MS250 probe
was set at 18 mm.
For all experiments, radiofrequency (RF) signals were
reconstructed from I/Q samples and further postprocessed
offline using MATLAB (The MathWorks, Natick, MA, USA).
Three regions of interest (ROIs) were selected within the tube
containing the UCA: ROI 1 was centered at 15 mm; ROI 2 at
18 mm (focal point); and ROI 3 at 21 mm. Two hundred RF
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lines were averaged in the frequency domain for analysis of
UCA responses at the fundamental (15 or 30 MHz) and SH
(15 MHz) frequencies within each ROI.
RF data were digitally bandpass filtered around SH frequen-
cies in the frequency domain, with a fifth-order Butterworth
filter. The −6-dB frequency cutoff for the SH filter was chosen
from 13 to 17 MHz. One should note that, in our analyses,
the signals at the fundamental frequency (30 MHz) correspond
to the nonlinear behavior of the UCAs at that frequency and
not the linear backscattered signal. This is because the analyses
were performed on the RF signals reconstructed from the pulse
inversion sequence, which removes the linear components of
the backscattered signal at the fundamental frequency [38].
C. In Vivo hfCEUS Imaging and Quantification
The animal protocol was approved by the animal ethics
committee of the Erasmus MC (EMC3379 142-14-01) and
conducted in strict accordance to the National Guidelines
for Animal Care and Handling. After overnight fasting with
free access to water, the female pigs (crossbred Landrace ×
Yorkshire, 3–4 months of age) of approximately 30 kg (n = 4)
were premedicated with an intramuscular injection of tileta-
mine (5 mg/kg), zolazepam (5 mg/kg) (Zoletil, both Virbac
Laboratories, Carros, France), and xylazine (2.25 mg/kg)
(Sedazine 2%, AST Farma BV Oudewater, the Netherlands).
Anesthesia was maintained with a combination of intravenous
infusion of midazolam (1.5 mg/kg/h, Actavis, New Jersey,
USA), ketamine (5 mg/kg/h, Alfasan, Woerden, the Nether-
lands), sufentanil (4 µg/kg/h, Sufenta Fort, Janssen Pharma-
ceuticals Ltd., USA), and rocuronium bromide (4 mg/kg/h,
Fresenius Kabi, Germany) through an ear vein cannula. The
animals were ventilated through an endotracheal tube (7.0 Fr),
placed in the trachea via midline cervical tracheostomy in a
volume controlled mode (Servo 300, Siemens-Elema, Solna,
Sweden) with a fraction of inspired oxygen of 0.40, a fre-
quency to achieve normocapnia, and a positive end-expiratory
pressure of 5 cm H2O. Surgery via the right flank was
performed to expose the right kidney. hfCEUS imaging was
performed by manually injecting a 1 mL UCA bolus in the
jugular vein followed by a 10 mL 0.9% sodium chloride
flush. The performance of selected in-house produced UCA
formulations (F and L) was compared with that of Target-
Ready MicroMarker. The order in which they were injected
was random. The nonlinear hfCEUS measurements were
recorded using the Vevo2100 equipped with an MS250 trans-
ducer [18-MHz transmit frequency, 10 frames/s, 10% power,
∼400 kPa (MI < 0.1)]. The Vevo2100 uses the amplitude mod-
ulation pulse sequence in the nonlinear contrast imaging mode,
which mainly detects the nonlinear fundamental component of
the UCA [12]. Immediately after injection of the UCA into the
catheter, the ventilation of the animal was paused to minimize
movement due to breathing. After 25–30 s, the measurement
had been completed and the ventilation was turned on again.
Cine loops of side-by-side B-mode and nonlinear contrast
mode images were stored as lossless DICOM images for
further offline analysis using MATLAB. First, correction for
tissue motion in the imaging plane was applied as described
TABLE II
UCA FORMULATIONS: MEAN ± SD MICROBUBBLE
CONCENTRATION, SIZE, AND SPAN
previously [39], [40]. Briefly, the motion pattern of tissue in
the field of view was extracted from the B-mode images and
applied to the contrast mode images to correct for the motion
in the field of view. Three ROIs were chosen for every DICOM
recording at a depth of 0.5–5, 5–9, and 9–13.5 mm. For each
ROI, all pixel intensities were summed and normalized to the
area of the ROI. The intensity in each frame was obtained
to construct a time-intensity curve (TIC), the frames with the
maximum intensity were detected, and the mean intensity and
SD of this frame and the five frames before and after this frame
were calculated. In addition, alternative ROIs were chosen to
compare contrast enhancement in the artery with that in the
microcirculation where no clear vascularity was visible. The
ratio between the intensities in these ROIs was used to quantify
the ability to discriminate the blood vessels from the peripheral
enhancement.
D. Statistics
The ratios for the arteries and microvasculature of Target-
Ready MicroMarker and UCA formulation F were tested
for significance using paired-samples student’s t-tests, after
first ensuring that the data were normally distributed using
Shapiro–Wilk normality tests. A p-value <0.05 was regarded
as indicating significance.
III. RESULTS
A. Ultrasound Contrast Agent Preparation
After production, all UCA formulations appeared white as
shown in supporting Fig. 1(a) and (b), indicating that UCAs
could be produced with all 12 formulations. UCA formulations
D and J were least white. In addition, both these formulations
had the smallest layer of microbubbles at the top of the
aqueous solution in the vial after leaving the vials on the
bench for 2 h [supporting Fig. 1(c) and (d)], suggesting a
lower amount of microbubbles in these formulations.
The number weighted size distribution of UCA formulations
A-L and Target-Ready MicroMarker are shown in Fig. 2;
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Fig. 2. Number weighted size distributions of (a) DSPC-based UCAs made
by sonication (UCA type A, B, and C), (b) DSPC-based UCAs made by
vial shaking (UCA type D, E, and F), (c) DPPC-based UCAs made by
sonication (UCA type G, H, and I), and (d) DPPC-based UCAs made by vial
shaking (UCA type J, K, and L) all compared with Target-Ready MicroMarker.
the volume weighted size distribution is shown in support-
ing Fig. 2. None of the A-L type UCA formulations had
a number weighted mean diameter, volume weighted mean
diameter, or size distribution identical to that of Target-
Ready MicroMarker. UCA formulations A-C and G-I made
by sonication [Fig. 2(a) and (c)] contained higher amounts
of large microbubbles than Target-Ready MicroMarker. All
the UCAs produced by sonication had two distinct peaks in
their size distribution (0.4–0.5 and 2–3 µm). Longer sonication
times did not alter the mean number weighted diameter
much, as shown in Table II. The volume weighted diameter
decreased upon longer sonication times, while the concentra-
tion of microbubbles increased. UCA formulations D-F and
J-L made by vial shaking resulted in smaller microbubbles
[Figs. 2(b) and 2(d); Table II] than when microbubbles were
made by sonication. DSPC or DPPC as main coating resulted
in microbubbles of similar mean number weighted diameters
for both UCA production methods (Table II). The highest
microbubble concentration was found in UCA formulation
E. Microbubbles with the smallest mean number weighted
diameter were found in UCA formulation D and J, while this
was UCA formulation L for microbubbles with the smallest
mean volume weighted diameter, all of which were produced
by vial shaking. The highest mean number weighted diameters
were found in formulations B and H, and the highest volume
weighted diameter was found in UCA formulation J. The UCA
formulation with the smallest SPAN was formulation D, while
formulation F had the largest SPAN.
B. In Vitro hfCEUS
As shown in Fig. 3, different ultrasound scattering
intensities of UCA formulations A-L were observed at
15 MHz in vitro. The error bars in Fig. 3 represent the
variation in B-mode signal intensity within the ROI (the entire
cross section of the cylindrical tube containing the UCA). For
both the DSPC-based and DPPC-based UCA formulations,
Fig. 3. Ultrasound intensities (dB) at 15 MHz for UCA formulations A-L.
Intensities obtained from the PBS control were subtracted from the intensities
obtained from the UCA formulations. A-F type UCAs had DSPC as the main
coating lipid, while this was DPPC for G-L type UCAs.
microbubbles with larger mean diameters resulted in slightly
higher intensities. In addition, UCAs produced by sonication
that had similar mean number weighted diameters also showed
similar signal intensity in the B-mode scan (A, B, C and G,
H, I in Fig. 3). UCA formulation F had the highest signal of
the DSPC-based UCAs made by vial shaking, while this was
formulation K for the DPPC-based UCAs. However, a large
SD was observed for formulation K, due to a nonuniform sig-
nal throughout the tube. Two UCA formulations produced by
sonication and two produced by vial shaking were selected for
further studies. Based on the results so far, UCA formulations
C and I were selected out of the sonication produced UCAs
as they contained the highest concentration of microbubbles.
For the vial shaking produced UCAs, formulations F and L
were selected because they gave the highest ultrasound signal
in B-mode with the smallest SD.
Images of UCA formulations C, F, I, and L, and Target-
Ready MicroMarker at high and low concentrations, filtered
around their SH frequency (15 MHz), and the corresponding
frequency spectra for the three ROIs are presented in Fig. 4.
At high UCA concentration, attenuation was dominant for
formulations C, I, and L. This attenuation effect is also
reflected in the corresponding spectra of these UCAs, where
the amplitude of the spectra at the SH frequency drops about
10 dB for the deeper ROIs with respect to the highest SH
amplitude. Target-Ready MicroMarker and UCA formulation
F at high concentration had the highest and most homogeneous
SH response throughout the three ROIs. At low UCA concen-
tration, the attenuation effect was less pronounced. The SH
amplitude of Target-Ready MicroMarker dropped about 11 dB
when UCA concentration was reduced by a factor of 20. The
SH amplitude of UCA formulation I at such low concentration
was 10 dB higher than that for Target-Ready MicroMarker and
was homogeneous throughout the UCA area.
In all the corresponding spectra of the UCA signals in both
high and low concentration, the amplitude of the nonlinear
fundamental signal was maximal at the focus of the transducer,
where the acoustic energy was at its maximum (ROI 2).
At high concentrations, Target-Ready MicroMarker showed
560 IEEE TRANSACTIONS ON ULTRASONICS, FERROELECTRICS, AND FREQUENCY CONTROL, VOL. 64, NO. 3, MARCH 2017
Fig. 4. In vitro SH images of Target-Ready MicroMarker and for-
mulation C, I, F, and L at high (8.0 × 106 microbubbles/mL) and low
(4.0×105 microbubbles/mL) concentrations (top) and the corresponding spec-
tra of each ROI at three depths for each image (bottom).
the highest nonlinear response at the fundamental frequency.
However, at low concentration, all our in-house produced
UCAs had higher nonlinear responses at the fundamental
frequency than Target-Ready MicroMarker. The attenuation
effect was similar for the SH response and the nonlinear
fundamental response. UCA formulations C, I, and L showed
higher attenuation than Target-Ready MicroMarker and UCA
formulation F.
C. In Vivo hfCEUS
Of the four formulations that were studied in vitro for their
SH and nonlinear fundamental response, the two best per-
forming UCA formulations were selected for in vivo hfCEUS
studies: F and L. This decision was based on the fact that both
the acoustic signal and microbubble size distribution resem-
bled Target-Ready MicroMarker the closest. Fig. 5 shows the
result of the comparison between Target-Ready MicroMarker
and UCA formulations F and L in the same animal (n = 1).
For each recording, three ROIs were drawn: in the focal
region (blue), in the middle of the field of view (red), and the
bottom of the field of view (yellow). The mean ± SD intensity
in each ROI is shown in Fig. 5 (bottom) for all three UCAs.
hfCEUS images revealed slightly lower overall intensities
for UCA formulation F than for Target-Ready MicroMarker.
Formulation L on the other hand revealed only two larger
vessels in ROI3, while hardly any intensity increase was
observed outside these vessels or in ROI1 and ROI2. Because
contrast enhancement of UCA formulation L was negligible,
only Target-Ready MicroMarker and UCA formulation F were
further evaluated. The TICs corresponding to the example
in Fig. 5 for Target-Ready MicroMarker (gray) and UCA
formulation F (black) show very similar behavior between both
UCAs in all three ROIs (Fig. 6).
Fig. 5. Examples of in vivo hfCEUS measurements of Target-Ready
MicroMarker and formulations F and L in the kidney of the same animal.
The maximum intensity projection is shown. The bottom graph shows the
quantification of intensities in the three different ROIs of which the colors
correspond to those in the maximum intensity projections.
The experiments comparing Target-Ready MicroMarker and
formulation F (n = 7 in total) confirmed the observation
that the total contrast enhancement of Target-Ready Micro-
Marker was higher, although the difference was lower in
ROI3 (Fig. 7).
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Fig. 6. TICs of Target-Ready MicroMarker (gray) and UCA formulation F
(black) for the different ROIs. The TICs correspond to the same injections as
the example shown in Fig. 5.
Fig. 7. Complete comparison of Target-Ready MicroMarker and UCA formu-
lation F. The markers indicate the mean peak intensity of each measurement,
and the bars indicate the corresponding SD (n = 7). The symbols indicate
the data obtained from the same paired injection, whereas ∇ indicates the
example shown in Fig. 5 (measurement 1, animal a). Measurement 2 was
done in animal b and measurement 3–7 in animal c.
This implies lower attenuation for UCA formulation F
than for Target-Ready MicroMarker. Since UCA formulation
F seemed to better visualize the larger vessels and Target-
Ready MicroMarker resulted in more enhancement in the
microvasculature (see Fig. 5), we quantified the ratio between
enhancement in the arteries and the microvasculature for
all injections. The symbols that are used in Fig. 7 corre-
spond to those in Fig. 8, and quantification of the example
in Fig. 5 (∇) shows better discrimination of the artery from
the microvasculature for UCA formulation F. Although this
example showed a clear difference, overall the differences
Fig. 8. Comparison of the ratios of contrast enhancement in the arteries and
the microvasculature between Target-Ready MicroMarker (gray) and UCA
formulation F (white). The symbols, identical to the symbols in Fig. 7, indicate
the data obtained from the same paired injection, whereas ∇ indicates the
example shown in Fig. 5 (measurement 1, animal a). Measurement 2 was
done in animal b and measurement 3–7 in animal c. The lines connect the
paired injections (injected in random order). Differences between the two
UCAs were not significant.
Fig. 9. Repeated injections (n = 3) of UCA formulation F in the same
animal. For each injection, contrast enhancement decreased.
between Target-Ready MicroMarker and UCA formulation F
were not significant (p > 0.05).
We also verified the reproducibility of UCA formulation
F by repetitive injection in the same animal (n = 3) and
found similar intensities in ROI1 and ROI3 between the first
and second injection (Fig. 9). In ROI2, the second injection
was 17% lower than the first injection. The third injection
was 39% lower than the first injection in ROI1, 31% lower
in ROI2, and only 11% lower in ROI3. We verified that the
baseline values before the start of each measurement were
comparable. Reproducibility for Target-Ready MicroMarker
was not studied.
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IV. DISCUSSION
In this paper, we showed that one of our in-house produced
UCAs for hfCEUS resembled the performance of the com-
mercially available Target-Ready MicroMarker both in vitro
and in vivo. The best performing UCA was produced by 45 s
vial shaking and consisted of 92.4% DSPC and 7.6% DSPE-
PEG2000, in an aqueous solution of 70% PBS, 10% glycerol,
and 20% propylene glycol with a C4F10 gas core.
A. Ultrasound Contrast Agent Preparation
In our study, microbubble diameters were larger for
sonication produced UCAs than when microbubbles were
produced by vial shaking, which is in line with what
Sirsi et al. [33] found for their in-house produced UCAs with
a coating of DSPC and PEG-40 stearate (9:1 molar ratio)
and C4F10 gas core. In contrast, Moran et al. [34] reported
similar number weighted mean diameters of ∼0.5 µm for
their in-house produced UCAs by sonication and vial shaking.
Their nitrogen-filled microbubbles had a coating of dipalmi-
toyl phosphatidylethanolamine (DPPE), phosphatidylcholine,
dipalmitoyl phosphatidyl-DL-glycerol, and cholesterol. The
contrasting findings in microbubble diameters between the two
production methods, i.e., sonication and vial shaking, suggest
that the microbubble composition and gas core may also play
a role in the size of the produced microbubbles. On the
other hand, different probe-sonication devices were used in
these studies (Sonicator Ultrasonic Processor XL2020 in our
study; Branson Ultrasonics Model 250 A in [33] and [41];
and Soniprep 150 in [34]), which could have given different
ultrasonic power outputs thereby influencing the microbubble
size distribution [28].
Kooiman et al. [29] reported that 10-s sonication for
the same UCA formulations as A-C (DSPC-based) and G-I
(DPPC-based) resulted in microbubbles with a mean number
weighted diameter of 4.2 and 3.9 µm, respectively. Although
sonication for 60 s resulted in smaller microbubbles (∼2 µm
in mean number weighted diameter; see Table II), the number
weighted mean diameter was similar after 60-, 90-, or 120-s
sonication. This was also observed by Moran et al. [34] who
reported that the number weighted mean diameter of ∼0.5 µm
did not change when the sonication time was varied among 30,
60, 90, or 300 s for their lipid-coated microbubbles (coating
composition see above). However, the number weighted size
distribution of our UCAs produced by sonication had two
peaks (0.4–0.5 and 23 µm; Fig. 2). A longer sonication
time seemed to produce lower amounts of large microbubbles
(>2 µm) and more microbubbles in between the peaks
(0.5–2 µm). This result is confirmed with the changes in
the volume weighted mean diameters, which decreased with
increasing sonication time. In addition, microbubble concen-
trations increased for longer sonication times. It is likely that
more microbubbles can be produced during longer sonication
times because excess unincorporated lipids are always present
when microbubbles are made by sonication [42]. The increase
in the concentration and the changes in the size distribution
of the UCA suggest that longer sonication times can break up
bigger microbubbles into smaller ones.
Our in-house produced UCA formulations D and J were
made by vial shaking in the absence of glycerol and propylene
glycol, just as Sirsi et al. [33] and Moran et al. [34] did.
On the other hand, glycerol and propylene glycol are often
added to increase the fluid viscosity when making UCAs in-
house by vial shaking [30], [35]–[37] and are also present in
the clinically approved Definity [21]. When the concentrations
of glycerol and propylene glycol were increased from 0%/0%
to 5%/5% and 10%/20% v/v, we found varying results on
microbubble size and concentration. For the DPPC-based
UCAs (formulations J, K, and L), increasing the concentration
of glycerol and propylene glycol increased the microbubble
concentration and the number weighted mean diameter. For
the DSPC-based UCAs (formulations D, E, and F), the number
weighted mean diameter followed the same trend. The concen-
tration of the microbubbles, on the other hand, first increased
with 5%/5% glycerol and propylene glycol and decreased
for the highest concentration. In addition, UCA formulations
F and L were more stable after 2 h than those without
glycerol and propylene glycol. This suggests that glycerol and
propylene glycol can play a role not only in increasing the
concentration of the microbubbles, but also on the stability of
the produced microbubbles. This increased stability of UCA
formulations F and L was also observed in the increased
intensity in the in vitro B-mode images of these UCAs.
B. In Vitro hfCEUS
In an in vitro setup, mimicking a practical imaging con-
dition, we showed that both the shell microstructure of
microbubbles as well as their size distribution have a consid-
erable impact on their nonlinear behavior both at the SH and
fundamental frequencies. All our homemade UCAs showed
high nonlinear behavior when excited at 30 MHz, which
was comparable with the commercially available Target-Ready
MicroMarker. Such high nonlinear response at both the SH and
fundamental frequencies can be attributed to the small sizes of
all studied microbubbles. The larger microbubbles in formu-
lations C and I (2–3 µm) accounted for more attenuation at
high concentrations. This hypothesis is confirmed by the lower
attenuation of the smaller microbubbles in UCAs F and L,
while the nonlinear responses remained high. The attenuation
effect was more pronounced for the SH component than the
nonlinear responses at the fundamental frequency. This is
perhaps due to the threshold behavior of SH oscillations [14].
The microbubbles at the lower part of the focal zone may not
have been excited with sufficiently high pressures to undergo
SH oscillation. However, when the concentration was 20×
lower, the SH response of these larger microbubbles became
stronger and more homogeneous throughout the sample.
Comparison of UCA formulations C and I with similar size
distributions but different main lipid component showed that
the DPPC-based UCA formulation I showed higher nonlinear
responses at both the fundamental and SH frequencies. At low
concentration, the response of UCA formulation I at the funda-
mental and SH frequency was 6 and 3 dB higher, respectively,
than for the DSPC-based UCA formulation C. This higher SH
response has also been reported in [20] utilizing optical single
microbubble spectroscopy in the range of 1–4 MHz.
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The small size of Target-Ready MicroMarker microbubbles
seems to play an important role in its nonlinear behavior,
particularly for the SH response at high-frequency excitation.
The majority of the microbubbles have a diameter below
1.5 µm, corresponding to a resonance frequency around and
higher than 15 MHz [43], [44]. It is conventionally thought that
SH generation is achieved most readily (i.e., at lowest pres-
sure threshold) when microbubbles are excited at twice their
resonance frequency [16]. This means that for the majority
of the Target-Ready MicroMarker microbubbles, the 30-MHz
excitation used in this paper is around twice their resonance
frequency. Indeed, high amplitude SH response of Target-
Ready MicroMarker UCA has previously been reported by
Helfield et al. [19], although they studied individual microbub-
bles in an acoustical setup. Another reason for the high SH
behavior of the UCAs we observed may be the rectangular
shape of the excitation used in the Vevo2100 scanner. It has
been reported that rectangular-shaped excitations generate a
self-demodulation signal, which enhances the SH response of
microbubbles [14], [15]. Our in vitro results show that Target-
Ready MicroMarker is also producing a strong nonlinear
response at the fundamental frequency. This characteristic is
already being utilized in the Vevo2100 scanner as the default
nonlinear contrast mode with amplitude modulation pulse
sequence to improve the contrast to tissue ratio in hfCEUS.
It has been shown before that smaller microbubbles pro-
vide higher contrast for hfCEUS imaging. Goertz et al. [45]
reported that the decantation technique to isolate smaller
Definity microbubbles can be employed to produce an atten-
uation pattern that appears more favorable for hfCEUS.
Also Moran et al. [34] have shown that decreasing the
mean diameter of the lipid-based sonication UCAs signifi-
cantly increased the mean backscattering power at 40 MHz.
Peyman et al. [46] showed that the majority of the signal
measured using the VisualSonics Vevo770 (40 MHz) in the
mixed microbubble/nanobubble population was attributable to
the nanobubbles, with a much lower proportion of the signal
coming from microbubbles. Our results are in agreement with
these studies.
We showed that at 30-MHz transmit frequency and at
low UCA concentration, DPPC-based UCAs behaved more
nonlinearly than those based on DSPC. At higher concentra-
tion, smaller microbubbles (Target-Ready MicroMarker and
UCA formulation F) produced the most homogeneous SH
responses. For UCA formulations C and I, Kooiman et al. [29]
observed differences in lipid distribution. The DPPC lipid has
a lower elastic compressibility modulus than DSPC [47], [48],
which may be related to SH behavior as our DPPC-based
UCAs showed more SH behavior than our DSPC-based UCAs,
as reported before for single microbubbles [20]. Unfortunately,
the coating composition of Target-Ready MicroMarker is
unknown, so we do not know how our homemade UCAs
resemble the composition of Target-Ready MicroMarker.
C. In Vivo hfCEUS
We studied UCA formulations F and L in vivo and found
that the overall performance of UCA formulation F was similar
to that of Target-Ready MicroMarker. UCA formulation L,
on the other hand, resulted in hardly any contrast enhancement
despite the fact that both in-house produced UCAs had similar
number-weighted mean diameters and the concentration of
microbubbles was even higher for UCA formulation L. The
most important difference between the two UCAs is their
composition and the associated differences between DSPC as
main component (formulation F) and DPPC (formulation L) in
terms of microstructure [29, [49]–[51] and acoustic behavior
in vitro [20]. Using an Acuson Sequoia 512 in nonlinear
imaging mode at 7 MHz (15L8 transducer), the in vitro half-
life of DPPC-based UCAs (DPPC:DSPE-PEG5000, 9:1, in-
house produced by vial shaking) was 10× lower than for
those based on DSPC, whereas the half-life was better in
vivo, but still 5× lower than for DSPC-based UCAs [52].
Although these and our in-house produced DPPC-based UCAs
did not perform well in vivo, the commercially available and
clinically approved UCA Definity that is also DPPC-based [21]
has been shown to provide good contrast enhancement in
pigs [53] and humans [54], [55]. It has to be noted that
the other components of Definity are DPPA and DPPE-
mPEG5000 [21], which can alter the acoustic properties and
stability.
Other research groups have also characterized their own in-
house produced UCAs for hfCEUS, but either characterized
them acoustically in vitro [19], [20], [46], [56]–[58] and/or
imaged them in vivo [33], [46], instead of imaging them
in both situations. Although acoustic characterization of sin-
gle microbubbles provides insights in microbubble behavior,
imaging of microbubbles in vitro in a controlled and sim-
plified setup is essential before translation toward complex
in vivo applications. Neither in vivo studies compared their
in-house produced UCAs to a commercially available UCA
as a reference. Peyman et al. [46] imaged their microbub-
bles (DPPC:DSPE-PEG2000, 4:1, microfluidic production) in
the mouse aorta at 40 MHz in fundamental mode using the
Vevo770, which resulted in hardly any contrast enhancement.
Simultaneously, with their microbubbles, they also produced
nanobubbles (∼200-nm diameter), which provided 3× higher
contrast peak intensities. Sirsi et al. [33] isolated microbub-
bles (DSPC:PEG40-stearate, 9:1 molar ratio, both sonication
and vial shaking) of distinct size populations (1-2, 2-4, and
6-8 µm) and determined their acoustic impact directly in vivo
in the mouse kidney using 40-MHz fundamental mode imag-
ing using the Vevo770. Surprisingly, they report that the
smaller microbubbles (1–2 µm) resulted in higher attenuation
and less echogenicity than the larger microbubbles (6–8 µm).
One reason for these contradictory results could be the differ-
ences in microbubble shell composition in these studies. Also,
in the study conducted by Sirsi et al. [33], the targets were the
small capillaries in the mouse kidney, while Peyman et al. [46]
quantified the UCA contrast in the mouse aorta that is a much
larger vessel. Both the concentration of the microbubbles in
the ROI and the differences in ambient pressures in kidney
capillaries and the aorta could have played a role in these
contradictory findings.
The TICs of UCA formulation F and Target-Ready
MicroMarker were very similar, but slightly higher peaks
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and longer contrast persistence were found for Target-Ready
MicroMarker. The prolonged contrast enhancement is likely
due to the higher acoustic stability of Target-Ready Micro-
Marker. These microbubbles not only contain a lipid shell,
but are also covered by streptavidin, which has been shown to
increase the stiffness and therefore reduce acoustic dissolution
in vitro [24]. The higher contrast peak intensity for Target-
Ready MicroMarker was shown to be present for all injections,
but the difference with UCA formulation F was smaller in the
deeper cortex. This may result from the higher concentration
of formulation F microbubbles that were injected and appeared
in the large vessels in the deeper cortex. The differences in
concentration between Target-Ready MicroMarker and UCA
formulation F influenced the interpretation of our results.
We concluded that the performance between both UCAs
was comparable, but it has to be taken into account that
an injection of 1 mL UCA formulation F contained ∼7×
more microbubbles than 1 mL of Target-Ready MicroMarker.
However, both concentrations are the same order of magnitude
as the commercially available ones, since a typical human dose
of Definity contains 4.2 × 109 microbubbles [21] and a typical
dose of SonoVue/Lumason varies between 3.0 × 108 and
1.1 × 109 microbubbles [27]. In addition, the concentration of
microbubbles between batches of Target-Ready MicroMarker
that were used in our experiments varied between 2.6 × 108
and 1.3 × 109 microbubbles/mL (n = 5). These concentrations
were assessed by us and are in line with what others have
reported, namely, 8.4 × 108 [25], 9.2 × 108 [59], and
1.9 × 109 [60]. The batch to batch variability in microbub-
ble concentration for our UCA formulation F ranged from
2.1 × 109 to 5.5 × 109 microbubbles/mL (n = 5 batches)
and was therefore narrower than for Target-Ready Micro-
Marker. The variation in the mean microbubble diameter (both
number and volume weighted) was similar for Target-Ready
MicroMarker and our in-house produced UCA formulation
F. The number weighted mean diameter for Target-Ready
MicroMarker was 1.8 ± 0.4 and the volume-weighted mean
diameter was 4.6 ± 0.8, while this was 1.2 ± 0.1 and
5.6 ± 1.0 for our in-house produced F type UCA (both n =
5 batches). The variability in microbubble size and concen-
tration can be caused by vial handling, even within manufac-
turer’s recommended procedures, as has been suggested by
Goertz et al. [45].
Repeated bolus injections of UCA formulation F in the
same animal resulted in significantly less enhancement for
the third injection. Others have reported differences between
consecutive injections in cats [61] and mice [62], [63]. In the
kidney and spleen of healthy cats, the second bolus injec-
tion of SonoVue resulted in higher peak intensities [61].
Dizeux et al. [63] reported that the maximum intensity (peak
enhancement) was constant for four consecutive injections in
the healthy renal murine cortex, but increased from the second
to the fourth injection in renal tumor tissue. In contrast,
Rix et al. [62] reported constant peak enhancement in murine
liver tumors and decreasing peak enhancement with consecu-
tive injections in the healthy liver. We can only conclude that
variability in consecutive injections is a known issue for CEUS
and differs between organisms and organs.
D. Limitations
The main limitation of using in-house produced UCAs
is that it can be challenging to produce them under good
manufacturing practice conditions [64]. For example, batch to
batch reproducibility may be an issue, as is sterility. However,
for terminal preclinical experiments as in our study, the UCAs
do not have to be sterile. For longitudinal preclinical experi-
ments, there are options for sterilization of lipid formulations
[65], [66]. In our in vivo experiments, we used nonlinear
fundamental imaging at 18 MHz with amplitude modulation
instead of SH imaging with pulse inversion at 30 MHz as
used in vitro. Although SH imaging is free from nonlinear
propagation artifacts, nonlinear fundamental imaging with
amplitude modulation provides higher contrast to tissue ratio
with Vevo2100 [15].
V. CONCLUSION
Our results suggest that our UCA formulation F performs
equally well as Target-Ready MicroMarker in hfCEUS imag-
ing. This paper shows that small UCAs having high nonlin-
ear responses for hfCEUS can be produced by mechanical
agitation, a shell composition of 92.4% DSPC, 6.4%
DSPE-PEG2000, and 1.2% DSPE-PEG2000-biotin encap-
sulating a C4F10 gas core, in a PBS-based liquid with
10% glycerol and 20% propylene glycol.
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